Mk0518
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
332 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 14 | 17 | 21 | 20 | 33 | 104 |
| Hiv | D006678 | — | O98.7 | 3 | 3 | 5 | 14 | 13 | 38 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 3 | 4 | 4 | 7 | 11 | 29 |
| Infections | D007239 | EFO_0000544 | — | 4 | 1 | 3 | 2 | 8 | 18 |
| Communicable diseases | D003141 | — | — | 3 | 1 | 3 | 1 | 5 | 13 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | 1 | 2 | 1 | 3 | 2 | 9 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | 1 | 1 | — | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | 1 | 1 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | 2 | — | 2 |
| Hiv seropositivity | D006679 | — | — | — | — | — | 1 | 1 | 2 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | — | 1 | 1 | — | — | 2 |
| Virus diseases | D014777 | — | B34 | — | — | 1 | — | 1 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | 1 | — | — | 1 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | 1 | — | — | 1 |
| Hyperlipoproteinemias | D006951 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 2 | 1 | — | — | — | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 1 | — | — | — | 2 |
| Fibrosis | D005355 | — | — | 1 | 1 | — | — | — | 2 |
| Hepatitis | D006505 | — | K75.9 | 1 | 1 | — | — | — | 2 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 1 | — | — | — | 2 |
| Lipodystrophy | D008060 | — | E88.1 | — | 1 | — | — | 1 | 2 |
| Viremia | D014766 | — | B34.9 | — | 1 | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | — | — | — | 1 |
| End stage liver disease | D058625 | EFO_1001311 | K72.1 | 1 | 1 | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Muscle spasticity | D009128 | — | — | 1 | — | — | — | — | 1 |
| Tropical spastic paraparesis | D015493 | EFO_0007527 | G04.1 | 1 | — | — | — | — | 1 |
| Htlv-i infections | D015490 | EFO_0007316 | — | 1 | — | — | — | — | 1 |
| Paraparesis | D020335 | — | G82.2 | 1 | — | — | — | — | 1 |
| Spastic paraparesis | D020336 | — | — | 1 | — | — | — | — | 1 |
| Hypercholesterolemia | D006937 | — | — | 1 | — | — | — | — | 1 |
| Papillomavirus infections | D030361 | — | — | 1 | — | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | 1 | — | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurotoxicity syndromes | D020258 | — | G92 | — | — | — | — | 1 | 1 |
| Morbidity | D009017 | — | — | — | — | — | — | 1 | 1 |
| Organ transplantation | D016377 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Proteinuria | D011507 | — | R80 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | — | — | 1 | 1 |
| Nerve degeneration | D009410 | — | — | — | — | — | — | 1 | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 1 | 1 |
| Neuroinflammatory diseases | D000090862 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use